FDA grants approval to Novartis’ radiotherapy Pluvicto for prostate cancer, with 2 billion dollars-plus highest sales expectations

FDA gave its approval of Novartis’ Pluvicto for patients who are suffering from (mCRPC) metastatic castration-resistant prostate cancer and have tested positive for its prostate-specific membrane antigen from an FDA-approved imaging diagnostic.

According to Novartis, Pluvicto can go over 2 billion dollars in top sales. In recent times, 851 million dollars have been allotted to the drug’s probable sales by 2026 by Evaluate Vantage. Novartis has a commercial team that emphasizes nuclear centers for the handling of supplies and logistics. It also has a devoted field sales team for prostate cancer.

This news update is an opportunity as well as an upcoming contract for Stevcon to apply its trusted expertise to further meet the demand of the nuclear medicine market nationwide.